KING OF PRUSSIA, PA — United BioSource LLC has moved to tighten its grip on one of biopharma’s most critical battlegrounds, acquiring Evidinno Outcomes Research Inc. in a deal that sharply expands its firepower in real-world evidence, health economics, and market access strategy.
Evidinno, headquartered in Vancouver, is known for producing the kind of regulatory-grade and health technology assessment evidence that increasingly determines whether new drugs are approved, reimbursed, and adopted. Its team of epidemiologists, health economists, and research scientists specializes in real-world evidence, comparative effectiveness research, network meta-analyses, and advanced economic modeling, tools that payers and regulators rely on to judge a therapy’s true value.
For UBC, the acquisition deepens its push to modernize how evidence is generated and used across the drug lifecycle, from late-stage development through post-approval market access. The company already works with biopharma clients to embed data acquisition into study design and execution, creating continuous streams of safety and effectiveness data. Adding Evidinno’s analytical and synthesis capabilities extends that model into the high-stakes realm of reimbursement and regulatory decision-making.
“Evidinno’s scientific rigor and technology-enabled workflows deepen our ability to curate fit-for-purpose evidence and health economic and outcomes insights for our clients,” said Aaron Berger, senior vice president of evidence development solutions at UBC. “Together, we will transform the evidence value chain and help sponsors answer important questions on the safety and effectiveness of treatments for patients.”
Evidinno brings to the table a portfolio that includes AI-supported literature reviews, health economic modeling, HTA dossier development, and research consulting across the product lifecycle. Those services are increasingly in demand as healthcare systems around the world move toward value-based reimbursement, where demonstrating real-world benefit is just as important as showing clinical efficacy.
Dr. Mir Sohail Fazeli, Evidinno’s chief executive, said joining UBC gives his firm a global platform to scale its scientific approach.
“By combining our HTA- and regulatory-grade evidence synthesis solutions, real-world research, and economic modeling capabilities with UBC’s global platform, we are well positioned to deliver robust, decision-ready evidence that supports sponsors and improves outcomes for patients worldwide,” he said.
Evidinno will operate as a wholly owned subsidiary within UBC, with the two companies offering an integrated suite of consulting and evidence generation services that span clinical development, regulatory strategy, and post-approval commercialization.
Fairmount Partners advised Evidinno on the transaction. Financial terms were not disclosed, but the strategic intent is clear: as drug pricing and access come under growing scrutiny, UBC is betting that control of the evidence pipeline will be as important as the science behind the drugs themselves.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.